|
ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
Disclaimer
ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | ||||
|
||||
Groundbreaking Research From NCNED: New Therapeutic Approach For ME/CFS
Tuesday 22 October 2019
From Australia's National Centre for Neuroimmunology and Emerging Diseases (NCNED) (via Facebook):
 |
GROUNDBREAKING RESEARCH FROM NCNED: NEW THERAPEUTIC APPROACH FOR ME/CFS
NCNED researchers have discovered the pharmacological drug known as Naltrexone restores the impaired TRPM3 biomarker function in immune cells from ME/CFS patients.
NCNED is the peak research centre nationally and is internationally recognised for its world-leading research on the identification of the pathology, developing a screening test and pharmacotherapeutic intervention for ME/CFS.
NCNED researchers were the first in the world to develop the gold-standard in experimental research known as patch clamp technique in immune cells to measure TRP receptor function.
Cabanas, H, Muraki, K, Staines, D and Marshall-Gradisnik, S published these important findings in Frontiers in Immunology. The full publication will be released in the coming weeks, however, the abstract is provided below:
https://www.frontiersin.org/articles/10.3389/fimmu.2019.02545/abstract
In this new pivotal research publication, Dr Cabanas and NCNED researchers report Naltrexone (NTX) restored TRPM3 activity in Natural Killer (NK) cells from ME/CFS patients. NCNED researchers use NK cells as a model for assessing TRPM3 and other TRP function and which reflects physiological activity in all body tissues expressing these ion channels.
This groundbreaking discovery used the advanced and gold-standard electrophysiology technique known as patch clamp in immune cells to confirm dysfunction of TRPM3 to be associated with ME/CFS pathology.
Importantly, NCNED researchers used Naltrexone, a known opioid antagonist used by ME/CFS patients, to restore significantly the impaired TRPM3 ion channel function in immune cells from ME/CFS patients.
This world first discovery suggests new potential pharmaco-therapeutic interventions in ME/CFS.
Thank you to the Stafford Fox Medical Research Foundation, Mr Douglas Stutt, the Mason Foundation, the McCusker Charitable Foundation, Mr Adrian Flack, Mr and Mrs Ian and Talei Stewart, the Alison Hunter Memorial Foundation, the Buxton Foundation, the Henty Community, the Blake Beckett Foundation, Change for ME Charity, QLD ME/CFS/FM Support Association QLD Inc, the ACT ME/CFS Society and WA ME/CFS.
blog comments powered by Disqus
Previous Page |
Registered Charity 3104
Email:
sacfs@sacfs.asn.au
Mailing address:
PO Box 322,
Modbury North,
South Australia 5092
Phone:
1300 128 339
Office Hours:
Monday - Friday,
10am - 4pm
(phone)